IND filing for paclitaxel injection product expected by year-end for ovarian cancer treatment. Paclimer's delivery system reduces the need for the high concentrations of paclitaxel in Bristol-Myers Squibb's Taxol that cause side effects, the company said. Paclimer would only require one or two injections during a 16-week period. Pre-clinical results of paclitaxel vs. Paclimer (4 mg/kg in both arms) showed 10% survival for paclitaxel at 120 days compared to 50% for Paclimer. At 40 mg/kg, paclitaxel showed 60% survival at 120 days compared to 90% for Paclimer
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth